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Abstract
Post-transcriptional regulation of HIV-1 gene expression is mediated by interactions between viral transcripts and
viral/cellular proteins. For HIV-1, post-transcriptional nuclear control allows for the export of intron-containing RNAs
which are normally retained in the nucleus. Specific signals on the viral RNAs, such as instability sequences (INS)
and Rev responsive element (RRE), are binding sites for viral and cellular factors that serve to regulate RNA-export.
The HIV-1 encoded viral Rev protein binds to the RRE found on unspliced and incompletely spliced viral RNAs.
Binding by Rev directs the export of these RNAs from the nucleus to the cytoplasm. Previously, Rev co-factors have
been found to include cellular factors such as CRM1, DDX3, PIMT and others. In this work, the nuclear matrix
protein Matrin 3 is shown to bind Rev/RRE-containing viral RNA. This binding interaction stabilizes unspliced and
partially spliced HIV-1 transcripts leading to increased cytoplasmic expression of these viral RNAs.
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Background
The nucleus is a highly organized structure. Chromo-
somes occupy discrete regions, and specific proteins and
nucleic acids are enriched in subnuclear structures such
as nuclear lamina, nucleoli, Cajal bodies, nuclear speck-
les, and paraspeckles [1-6]. The nuclear matrix, a net-
work of underlying filaments in the cell nucleus, shapes
the nuclear architecture and functions in genome main-
tenance, transcription and RNA metabolism [7-17].
Accordingly, the nuclear matrix has important roles in
tissue development and cellular proliferation; and the
disruption of nuclear organization is often correlated
with disease states such as the loss of subnuclear pro-
myelocytic leukemia bodies in acute promyelocytic leu-
kemia [18-21].
HIV-1 gene expression and replication are regulated at
transcriptional and post-transcriptional steps including
the transactivation of the HIV-1 LTR by Tat [22] and
the export of unspliced or partially spliced viral RNAs
from the nucleus to the cytoplasm by Rev [23-26]. Rev
is a trans-acting viral protein which binds to a cis-acting
Rev responsive element (RRE) present in unspliced and
partially spliced HIV transcripts. Rev has been shown to
interact with cellular proteins CRM1, DDX3, PIMT and
others to mediate the export of unspliced and singly
spliced viral RNAs [27-30]. The mechanism of viral
RNA export by Rev is discrete from the export pathways
used by fully spliced HIV-1 mRNAs, CTE- (constitutive
transport element) dependent RNAs, and cellular
mRNAs [31-43].
Recently, numerous studies have implicated the
nuclear matrix in gene transcription, RNA splicing, and
transport of cellular RNAs [5,7,9,44,45]; however, the
role of the nuclear matrix in HIV-1 gene expression has
been poorly explored [46-48]. Here, we identify Matrin
3 as a key component of factors that mediate the post-
transcriptional regulation of HIV-1. Matrin 3 is a highly
conserved inner nuclear matrix protein which has been
previously shown to play a role in transcription [49-52].
It interacts with other nuclear matrix proteins to form
the internal fibrogranular network; it acts in the nuclear
retention of promiscuously A-to-I edited RNAs in coop-
eration with p54(nrb) and PSF [53,54]; it participates in
NMDA-induced neuronal death; it modulates the pro-
moter activity of genes proximal to matrix/scaffold
attachment region (MAR/SAR)[ 5 5 ] ;a n di ti si n v o l v e d
in the repair of double strand breaks [56]. Our current
findings implicate that Matrin 3 also influences the
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Results
Matrin 3 enhances Rev/RRE directed gene expression
We identified Matrin 3 as a PTB-1 (polypyrimidine tract
binding protein -1) interacting protein in a yeast 2
h y b r i da s s a y( T a b l e1 ) .P T B- 1p l a y sar o l ei nt h ea l t e r -
native splicing of cellular mRNAs and has been
described to promote the expression of fully spliced
HIV-1 transcripts (our unpublished results and [57]). A
“PTB-1 associated splicing factor” [58] named PSF has
been proposed to inhibit the expression of HIV-1
unspliced/spliced transcripts [59]. We reasoned that like
PSF, Matrin 3 through its association with PTB-1 might
modulate HIV-1 gene expression.
To explore a role for Matrin 3 in HIV-1 replication,
we measured the effect of over expressed Matrin 3 on
viral Tat and Rev mediated gene expression. We
expressed Matrin 3 and Tat, either separately or
together, in HeLa cells with an HIV-1 LTR luciferase
plasmid and measured reporter-expression. As shown in
Figure 1A, Matrin 3 did not influence either basal LTR
expression or Tat activated expression, suggesting that it
does not act at the step of transcription.
We next investigated if Matrin 3 acts at steps post
transcription. Rev is required for the cytoplasmic locali-
zation of unspliced and partially spliced HIV-1 mRNAs
Table 1 List of Human and Mouse PTB-1 interacting proteins identified by yeast 2 hybrid assay.
PTB-1 interacting proteins identified by yeast 2 hybrid assay Other names/synonyms Accession #
A) Interacting with Human PTB-1
Aladin AAAS; adracalin NP_056480
Calcium and integrin binding 1 CIB1; CIB; kinase-interacting protein 1; KIP1 NP_006375
Cleavage stimulation factor, 3’ pre-RNA, subunit 2, 64 kD, tau CSTF2T; KIAA0689 NP_056050
Homeodomain-interacting protein kinase 1 isoform1 HIPK1; KIAA0630 NP_938009
Matrin 3 MATR3 NP_001181883
poly(rC) binding protein 1 PCBP1 NP_006187
RNA binding motif protein 10 RBM10 NP_005667
Exportin 1 CRM1; XPO1 NP_003391
heterogeneous nuclear ribonucleoprotein K, isoform b HNRPK NP_112552
heterogeneous nuclear ribonucleoprotein L HNRPL NP_001524
Raver1 Raver1 NP_597709
A) Interacting with Mouse PTB-1
arylhydrocarbon receptor nuclear translocator ARNT, hypoxia-inducible factor 1, beta subunit; dioxin receptor NP_001659
Calcium and integrin binding 1 CIB1; CIB; KINASE-INTERACTING PROTEIN 1; KIP1 NP_006375
DAZ associated protein 2 DAZAP2 NP_055579
nuclear receptor coactivator 6 NCOA6 NP_054790
Raver1 Raver1 NP_597709
Matrin 3 MATR3 NP_001181883
RNA binding motif protein 10 RBM10 NP_005667
fibrosin-1-like protein KIAA1545; FBRSL1 NP_001136113
protein BAT2-like 1 KIAA0515; BAT2L1 NP_037450
hexaribonucleotide binding protein 3 HRNBP3; RBFOX3; FOX3 NP_001076044
G protein pathway suppressor 2 GPS2 NP_004480
proline rich 3 PRR3 NP_079539
tripartite motif-containing 8 TRIM8 NP_112174
zinc finger, CCHC domain containing 2 ZCCHC2; NP_060212
zinc finger protein 36, C3H type, homolog ZFP36A, tristetraprolin; NUP475 NP_003398
neuro-oncological ventral antigen 1 NOVA1 NP_002506
neuro-oncological ventral antigen 2 NOVA2 NP_002507
Matrin 3 was identified to interact with both Human and Mouse PTB-1 (indicated in bold and italics. The yeast 2 hybrid screening was performed at Myriad
Pronet (Utah, USA) using human and mouse PTB-1 as bait. PTB-1 interacting proteins were identified using activation domain fused libraries obtained from
human spleen, brain and heart.
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Rev binds to an RRE-RNA motif in these RNAs [60,61].
Unlike fully spliced viral RNAs, these transcripts contain
cis-inhibitory RNA elements which restrict their export
from the nucleus into the cytoplasm in the absence of
Rev binding to the RRE motif. The binding of Rev to
the RRE frees this restriction, and Gag protein expres-
sion is thus increased by several fold compared to its
expression in the absence of Rev [60,61].
We checked if Matrin 3 affects Rev-mediated post-
transcriptional processes by using a CMV-promoter
driven Gag-Pol-RRE expression plasmid as a reporter.
HeLa cells were transfected with wild type and mutant
Matrin 3 together with pCMV Gag-Pol RRE, as indi-
cated; and 24 hours later, cells were harvested and cell
lysates were analyzed by Western blotting. Figure 1B
(lanes 1 and 2) shows that Matrin 3 did not alter the
expression of Gag in the absence of Rev; however, in
the presence of Rev, Matrin 3 increased Gag expres-
sion by approximately 10 fold (Figure 1B, lanes 3 and
4). These results support a role for Matrin 3 in Rev-
dependent expression of RRE-containing HIV-1
transcripts.
The CTE is a cis-motif found in RNAs from simple
type D retroviruses [32]. It recruits cellular RNA-bind-
ing proteins that act to export unspliced or partially
spliced viral mRNAs from the nucleus into the cyto-
plasm [39,41]. Artificial placement of the CTE into
HIV-1 Gag RNA facilitates its cytoplasmic export and
expression, independent of Rev/RRE function [32].
Indeed, CTE and Rev/RRE describe two separate path-
ways such that the inhibition of either pathway does not
affect the export of RNA through the other pathway
[34,35]. We next assayed a Gag expression vector in
which the RRE was replaced with a CTE. Unlike the
results from Gal-Pol-RRE (Figure 1b), we found that the
over expression of Matrin 3 had no effect on Gag-Pol-
CTE expression (Figure 1C, lanes 5 and 6).
It would be physiologically important to replicate the
observations made on the Gag-Pol reporters using a full
length HIV-1 infectious molecular clone, pNL4-3. We
thus transfected HeLa cells with pNL4-3 and either a
control vector or a Matrin 3 expressing vector. One day
after transfection, cell lysates were immunoblotted for
p24 Gag; and we found that Matrin 3 increased p24
Gag level by approximately 10 fold (Figure 2A). In a
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Figure 1 Matrin 3 promotes the expression of Rev dependent RRE containing transcripts. A) HeLa cells were transfected with Matrin 3
and Tat along with HIV-1 LTR luciferase. Luciferase assays performed on cell lysates prepared from these cells did not show any effect of Matrin
3 on Tat dependent LTR transactivation. B) Matrin 3 enhances the expression of RRE containing RNA transcripts in the presence of Rev in HeLa
cells. HeLa cells were transfected with 2.0 μg of Matrin 3 expression or control plasmid along with 0.5 μg of pCMV -GagPol-RRE plasmids in the
presence or absence of Rev. HA-Matrin 3 significantly increased the expression of Gag from the reporter construct pCMV-GagPol-RRE in the
presence of Rev (compare lanes 2 and 4). C) Gag expression from CTE containing pCMV-GagPol-CTE reporter was not effected by HA-Matrin 3
(compare lanes 5 and 6).
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Page 3 of 10complementary experiment, Matrin 3 RNA was knocked
down using specific siRNAs (Figure 2B). siRNA-
mediated knock down of Matrin 3 decreased HIV-1 p24
Gag expression from pNL4-3 by 3 to 4 fold (Figure 2B).
On the other hand, when Matrin 3 expression in
knocked down cells was reconstituted (Additional file 1,
Figure S1), HIV-1 gene expression was restored. Collec-
tively, the results are consistent with Matrin 3 selectively
acting on HIV-1 Rev/RRE - dependent post-transcrip-
tional events.
Matrin 3 interacts with Rev
How does Matrin 3 affect Rev/RRE-dependent expres-
sion? We wondered if Rev, Matrin 3 and RRE-contain-
ing RNA are together in a ribonucleoprotein complex.
To check this possibility, we transfected and immuno-
precipitated HeLa cells with EGFP-Rev with or without
Matrin 3 along with version so fH I V - 1G a gp 3 7c o n -
structs (Figure 3A) with or without RRE or CTE
[62-64]. The immunoprecipitates were then analyzed
by Western blotting using either anti-HA or anti-GFP.
Figure 3 shows that there was no interaction between
Rev and Matrin 3 (Figure 3B, lanes 7, 9, 10, 11, 12),
except when a p37-RRE plasmid was expressed
(p37RRE; Figure 3B, lane 8; top). This interaction was
not seen when a p37CTE plasmid was used in place of
p37RRE (Figure 3B, lanes 9) or when the p37 Gag
sequences were codon optimized to make the expres-
sion of the RNA transcripts Rev-independent (Figure
3B, lanes 10-12) [62-64]. Thus, our interpretation cur-
rently favors that the interaction of Matrin 3 and Rev
specifically requires the presence of a Rev-dependent
RRE-containing RNA (p37-RRE), but not a Rev-inde-
pendent RRE-containing RNA (p37-M1-10-RRE). In
our experiments, the p37 protein expression levels are
similar between p37-RRE, p37-CTE, (Figure 3B, lanes
8-9) and p37M1-10, p37M1-10-RRE and p37-M1-10-
CTE (Figure 3B, lanes 10-12); hence, the Matrin 3 -
Rev interaction is not influenced by the amount of p37
protein.
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Figure 2 Matrin 3 increases HIV-1 production from transiently tranfected HeLa cells. A) HeLa cells were transfected with pNL4-3 along
with WT Matrin 3, and the expression of viral proteins was analyzed on Western blots. Wild type HA-Matrin 3 (lane 2) enhanced viral protein
expression. B) Matrin 3 knockdown using siRNA efficiently decreased cell endogenous Matrin 3 (lanes 2 and 3; top panel). Controls were
scrambled irrelevant siRNAs. (lower two panels) HeLa cells were transfected with HIV-1 molecular clone pNL4-3 and either the control or the
siRNA targeting Matrin 3. Western blot analysis of cell lysates showed that siRNA-mediated Matrin 3 knockdown reduced HIV-1 expression as
indicated by decreased p24 expression (lanes 2 and 3). Loadings were normalized to b-actin.
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activity on Rev/RRE
The above results are consistent with Matrin 3 associating
with Rev and RRE-RNA to facilitate expression. A predic-
tion from these results is that an RNA-binding competent
Matrin 3 is needed for its activity on HIV-1 RNAs. To
address this notion, we constructed two Matrin 3 deletion
mutants as indicated in Figure 4A. Matrin 3 is an 847-
amino acid protein with two RNA recognition motifs
(RRM) contained in amino acids 399 to 567, and a bipar-
tite NLS in amino acids 586 - 612. The RRMs are required
for Matrin 3 to bind RNA. The two Matrin 3 deletion
mutants expressed well in human cells (Figure 4B). When
both were assayed in co-transfections with pNL4-3 (Figure
4C) and compared to the activity of wild type Matrin 3,
neither mutant was proficient in activating HIV-1 as mea-
sured by Gag p24 expression (Figure 4C). The mutants
showed expected localization in the nucleus (Additional
file 2 Figure S2). The results from the RRM mutants are
consistent with the notion that RNA-binding by Matrin 3
is required for its HIV-1 function.
Matrin 3 increases the stability and nuclear export of HIV-
1 RRE-containing transcripts
One consequence of Matrin 3 binding to RNA could
be the stabilization of RRE-containing transcript. To
check this possibility, we compared the expression of
RRE containing transcripts in HeLa cells transfected
with HA-Matrin 3 (Figure 5). In HIV-1, the unspliced,
partially spliced and fully spliced RNAs can be categor-
ized into three groups based on their sizes. The ~ 9 kb
unspliced RNA serves as the genomic RNA and also
encodes the Gag, Gag-Pol fusion proteins. A set of ~ 4
kb, singly spliced mRNAs encode for Env, Vpr, Vif and
Vpu. A group of fully spliced ~ 1.8 kb mRNAs encode
Tat, Rev and Nef. The 9 kb and 4 kb classes of
mRNAs contain the RRE element while the 1.8 kb
mRNAs do not. We analyzed the effect of Matrin 3 on
the expression of the 9 kb and 4 kb transcripts com-
pared to the Rev/RRE independent 1.8 kb group of
RNA. HeLa cells were transfected with pNL4-3 and
Matrin 3 for this analysis, and we analyzed 20 μgo f
total RNA by Northern blotting (Figure 5A). There
was an increase, in the HA-Matrin 3 transfected cells,
in the 9 kb unspliced and 4 kb singly-spliced RNA
transcripts (which contain RRE; ratios of 1:2.9 and
1:2.3 respectively; Figure 5A, bottom), compared to the
fully spliced 1.8 kb RNA (which does not contain RRE;
a ratio of 1:1.2; Figure 5A, bottom).
We next investigated the consequence of increased
Matrin 3 expression on cytoplasmic distribution of
unspliced versus spliced viral RNAs. We co-transfected
HeLa cells with pNL4-3 and Matrin 3, and fractionated
cellular RNAs into total, cytoplasmic, or nuclear
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Figure 3 Matrin 3 interacts with Rev in the presence of viral Rev-dependent RRE-containing RNA. A) Schematic representations of the
RNAs expressed from the various p37Gag constructs. B) Co-immunoprecipitation of GFP-Rev occurs only in the context of p37-RRE. HeLa cells
were transfected with either pCMV-HA (lanes 1-6), or pCMVHA-Matrin 3 (lane 7-12) and GFP-Rev (lanes 1-12) plasmids, along with the indicated
versions of a p37Gag expression construct (see panel A and as indicated). Cell lysates were subjected to immunoprecipitation with anti-HA
antibody. Western blot analysis of co-immunoprecipitations shows that interaction occurs between Rev and Matrin 3 in the presence of co-
transfected p37RRE (lane 8, top panel) construct, but not p37, p37CTE, or codon optimized P37 Gag constructs that are Rev-independent (lanes 7
and 9-12, top panel). Lower two panels show the expression of Rev and Matrin 3 in cell lysates used for the immunoprecipitations, and the
second panel from the top shows HA-Matrin 3 proteins recovered by the co-immunoprecipitations.
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Page 5 of 10constituents. We isolated the RNAs from these frac-
tions and analyzed them by qRT-PCR for the levels of
unspliced and spliced RNAs using primers specific for
the 9 kb or the 1.8 kb viral RNA. We used GAPDH as
a normalization control for our fractionation (GAPDH;
Figure 5B). Consistent with the Northern blot results,
there was a 3 fold increase in expression of unspliced
viral RNA in the cells (total 9 kb; Figure 5B), but inter-
estingly the amount of 9 kb viral RNA distributed into
the cytoplasm of pCMV-HA-Matrin 3 expressing cells
was 10 fold higher than that found in pCMV-HA
expressing cells (cytoplasmic 9 kb; Figure 5B; also see
Additional file 3, Figure S3). By contrast, the distribu-
tion and expression of spliced RNA remained
unchanged in the presence of increased Matrin 3
expression (1.8 kb; Figure 5B). These results are con-
sistent with the interpretation that Matrin 3 can selec-
tively stabilize and increase the nuclear to cytoplasmic
distribution of unspliced 9 kb vs. spliced 1.8 kb HIV-1
RNAs.
Discussion
Here, we have shown that nuclear matrix protein Matrin
3 influences the expression of HIV-1 RRE-containing
mRNAs. Matrin 3 acts post-transcriptionally via Rev/
RRE to increase the expression of HIV-1 Rev/RRE
dependent unspliced or partially spliced transcripts. This
activity requires Matrin 3 to bind Rev-dependent RRE-
containing RNA and appears to lead to the stabilization
and nuclear to cytoplasmic export of RRE-containing
HIV-1 transcripts.
Previously it was shown that Matrin 3 exists in cells
complexed with PSF (PTBP associated splicing factor)
and nrbp54 [53,65-67]. Others have found that PSF
binds to instability elements (INS) contained within the
HIV-1 transcripts and suppresses the expression of
these RNAs [59]. The INS elements are primarily pre-
sent in the RRE-containing unspliced and partially
spliced viral transcripts [31,64,68-72]. It is possible that
some of the effects that we have observed from Matrin
3 may be due to its interaction with PSF and p54nrb.
1           2            3      
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Figure 4 Matrin 3 RRMs are required for activity on HIV-1 RNA. A) Schematic representations of the RRM deletion mutants of Matrin 3. B)
Western blot verification of the comparable expression of transfected Matrin 3 deletion mutants. Loadings were normalized to b-actin (bottom
panel). C) Expression of wild type HA-Matrin 3 (lane 2), but not HA-Matrin 3 d264-595 (lane 3) nor HA-Matrin 3 d162-595 (lane 4), which lack the
RRMs activated HIV-1 gene expression as measured by viral p55 or p24 levels.
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sion of RNA expression has not been explored here, but
it remains important to establish and clarify this
mechanistic interaction in the future.
Our results are compatible with a model in which
Matrin 3 binds to RRE containing transcripts and stabi-
lizes them in the presence of Rev, which then directs
these viral transcripts for export out of the nucleus.
This interpretation is supported by our observation that
Rev - Matrin 3 interaction is RRE-RNA dependent, and
Matrin 3 activity requires the presence of Rev and RRE-
containing RNA. Further experiments are needed to
answer the mechanistic details of how Matrin 3 and Rev
cooperate in their interactions with RRE-containing
RNA. One intriguing finding is that Matrin 3 has been
identified as a constituent of the nuclear pore proteomes
[73]; this localization would be compatible with Matrin
3 being a part of an RNP-complex that exits the nucleus
into the cytoplasm through the nuclear pore. Also of
interest, Bushman et al. [74] recently performed a meta-
analysis of published genome-wide siRNA screening of
cellular factors important for HIV-1 replication. They
used a graph theory clustering algorithm (MCODE) to
assemble a HIV-1 host interactome in which nuclear
matrix structure (Matrin 3) was identified as an interac-
tor with the molecular chaperone cluster identified by
siRNA-screening as involved in the assembly of viral
proteins. Our evidence here for a role of Matrin 3 in
HIV-1 post-transcriptional RNA expression is consistent
with the above analysis. In conclusion, the implication
of Matrin 3 as an additional Rev co-factor adds further
complexity to the understanding of post-transcriptional
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Figure 5 Matrin 3 stabilizes RRE-containing RNA. A) (top) Schematic representations of the differently sized mRNA transcripts produced
during HIV-1 replication. The 9 kb (unspliced) and 4 kb (singly spliced) viral transcripts contain the RRE cis-element and require Rev protein for
expression. (bottom) HeLa cells were transfected with HIV-1 molecular clone pNL4-3 and either pCMV-HA or HA-Matrin 3 plasmids. Northern blot
analysis of whole cell RNA demonstrated increased expression of unspliced 9 kb HIV-1 transcript (lane 2). Relative changes in the expression of 9
kb and 1.8 kb HIV-1 RNAs in cells, with and without Matrin 3, are shown by the numbers on the right. B) Matrin 3 increased the stability and
promoted the nuclear export of HIV-1 unspliced RNA. HeLa cells were transfected with pNL4-3 with (red) or without (green) Matrin 3. RNA was
isolated from whole cell lysates as well as nuclear and cytoplasmic fractions. qRT-PCR analysis of HIV-1 RNA was performed using primers specific
for spliced and unspliced viral transcripts [29]. Transfection of Matrin 3 (red) resulted in modestly increased amounts of HIV-1 unspliced
transcripts in the cells (top left panel, total), and a much larger increase in the distribution of unspliced HIV-1 transcripts into cytoplasm (top
right panel, cytoplasmic). As control, Matrin 3 did not affect the stability or the distribution of GAPDH mRNA (bottom panels, GAPDH).
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Although it remains to be established, Matrin 3 may be
a cellular factor that counters the nuclear retention
through INS elements of HIV-1 unspliced/partially
spliced RNAs.
Materials and methods
Plasmids
Full-length Matrin 3 clone was purchased from Open
Biosystems and cloned into pCMV-HA vector (Clon-
tech) by PCR. HIV-1 LTR luciferase plasmid, pCMV-
NL-GagPol-RRE and pCMV-NL-GagPol-CTE were from
E. Freed and D. Rekosh. Plasmids p37 and p37RRE were
kindly provided by B. Felber [64] and cloned into
pcDNA3.
Cell Culture, Transfection, and Reporter Assays
Cell propagation, transfection, qRT-PCR and reporter
assays were as described previously [28,29]. All transfec-
tions were repeated three or more times and were nor-
malized to b-galactosidase activity expressed from a co-
transfected pCMV-b (Clontech).
Antibodies
Mouse monoclonal anti-HA (Sigma Chemical); mouse
monoclonal Matrin 3, (Abcam) and rabbit anti-GFP and
anti-HA (Cell Sciences) are commercially available.
Western Blotting, and Immunoprecipitation
Western blotting and immunoprecipitation were per-
formed as described previously [28,29]. Briefly, the cells
were washed twice with PBS and lysed with sample buf-
fer [100 mMTris (pH6.8), 4%SDS, 20% glycerol, 5% b-
mercaptoethanol, and 0.05% bromophenol blue]. Cell
lysates were boiled for 10 minutes, and loaded onto a
SDS/PAGE gel and electrophoresed. The gel was elec-
troblotted onto Immobilon-P membranes (Millipore)
and probed with the primary antibodies, followed by
incubation with anti-rabbit, anti-mouse, or anti-human
alkaline phosphatase-conjugated secondary antibody and
detected using a chemiluminescence substrate (Applied
Biosystems).
RNA isolation, Northern blotting and qRT-PCR
Total RNA from cells was extracted with Tri-Reagent
(Sigma-Aldrich). Nuclear and cytoplasmic RNAs were iso-
lated by cell fractionation (Paris Kit; Applied Biosystems),
and RNA was isolated with Tri-Reagent. Northern blots
were performed as described previously [28]. Extracted
RNA was analyzed by qRT-PCR using the iScript One-
Step RT-PCR Kit with SYBR Green (Bio-Rad) according
to manufacturer’s instructions. Samples were reverse-tran-
scribed at 50°C for 30 minutes, and amplification was per-
formed after an initial step at 95°C for 10 minutes,
followed by 20-40 cycles at 95°C for 30 s, 55°C for 30 s,
and 72°C for 60 s. The primers and their sequences used
in the analyses have been previously described [29]. Pri-
mers for unspliced transcripts were Primer A 5′-
GTCTCTCTGGTTAGACCAG-3′, Primer C 5′-CTAGT-
CAAAATTTTTGGCGTACTC-3′ and primer A and
sj4.7A 5′- TTGGGAGGTGGGTTGCTTTGATAGAG-3
for spliced 2 Kb transcript. For GAPDH forward 5′
CTCTGCTCCTCCTGTTCGAC 3′ and GAPDH reverse
5′ TTAAAAGCAGCCCTGGTGAC 3′ primers were used.
Co-immunoprecipitation
Co-immunoprecipitation assay has been described pre-
viously [28,29]. Cell lysates were prepared in RIPA buf-
fer [Tris-buffered saline (pH 8.0) containing 1% Triton
X - 1 0 0o rN o n i d e tP - 4 0 ,1m go fB S A / m L ,a n d1m M
EDTA] containing (phenylmethylsulfonyl fluoride and
aprotinin 10 μg/mL), 0.5% sodium deoxycholate, and
0.1% SDS. Cell lysates were prepared and incubated at
4°C overnight with the indicated antibodies and immune
complexes were pulled down using protein G-agarose
beads and analyzed by Western blotting.
Additional material
Additional file 1: Figure S1. Overexpression of Matrin 3 rescues
Matrin3 siRNA mediated suppression of HIV-1 gene expression.
HeLa cells were transfected with Matrin 3 siRNA along with pNL4-3 and
the indicated Matrin3 expression constructs. Cell lysates were collected
and analyzed by Western blotting. As shown the Matrin3 siRNA knocked
down cell endogenous Matrin3 (compare lane 1 and 2, middle panel),
but the overexpression of Matrin3 restored the Matrin3 levels in the cell
(compare lane 1 and 6 middle panel). Knockdown of Matrin3 suppressed
HIV-1 gene expression as indicated by measured p24 levels (lane 2);
conversely the increased expression of Matrin3 from transfected plasmids
restored HIV-1 gene expression (lane 6).
Additional file 2: Figure S2. Matrin 3 deletion mutants localize to
the nucleus. HeLa cells were transfected with the indicated Matrin 3
deletion mutants; cells were fixed and stained with anti-HA antibody and
alexa 488 tagged secondary antibody. Intracellular distribution of matrin3
was examined by confocal imaging.
Additional file 3: Figure S3. Matrin 3 increased the stability and
promoted the nuclear export of HIV-1 unspliced RNA. The
experiment in Figure 5B was repeated in triplicate, and qRT-PCR results
from two representative repeats are presented here. HeLa cells were
transfected with pNL4-3 along with (red) or without (green) Matrin 3.
RNA was isolated from whole cell lysates as well as nuclear and
cytoplasmic fractions. qRT-PCR analysis of HIV-1 RNA was performed
using primers specific for spliced and unspliced viral transcripts.
Transfection of Matrin 3 (red) resulted in modestly increased amounts of
HIV-1 unspliced transcripts in the cells (top left panels, total), and a much
larger increase in the distribution of unspliced HIV-1 transcripts into the
cytoplasm (top right panels, cytoplasmic). As control, Matrin 3 did not
affect the stability or the distribution of GAPDH mRNA (bottom panels,
GAPDH). RFU = relative fluorescent units.
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